Latest from Business Wire
Business Wire
an hour ago
- Health
- Business Wire
Mended Hearts International Foundation Will Be Launched to Empower Patients with Cardiovascular Diseases Worldwide
GENEVA--(BUSINESS WIRE)--For more than seven decades, patients with cardiovascular diseases have found hope through a simple but powerful concept: peer-to-peer support from those who have walked the same journey. Now, the mission of The Mended Hearts, Inc. (MHI) will expand globally with the establishment of the Mended Hearts International Foundation (MHIF). This independent, endowed, nonprofit foundation will be based in Geneva, Switzerland, and will work with national and international decision and policymakers — including politicians, legislators, professionals and associations — to develop healthcare policies and regulatory frameworks that support patient-centered care across multiple disease states, including heart disease, stroke, diabetes, obesity, chronic kidney diseases, cancers, sleep apnea and depression. The Foundation will participate in the Mended Hearts International Network (MHIN), which will include The Mended Hearts, Inc. (USA), Mended Hearts Europe (MHE) and Mended Hearts University, Inc. (MHU). Additional nonprofits are expected to join the MHIF, including Mended Little Hearts, Inc., Mended Hearts Asia and other nonprofit organizations. Overall, the MHIF will have four main mandates: Support patients and their families by creating an inclusive and compassionate community through peer-to-peer support and meaningful connections Empower patients and their families by providing relevant education and resources that enable them to make better decisions about their healthcare Develop educational research projects and rely on research and input from the patient communities, in particular through the entities of the Mended Hearts International Network Preserve the values and ethics of the Mended Hearts International Network Building on the success of MHI, the world's largest peer-to-peer cardiovascular patient support network, the MHIF will represent the natural evolution of expanding resources to support the 523 million patients, according to the CDC, who suffer with cardiovascular diseases worldwide. 'The MHIF believes in a world where every patient with cardiovascular disease is empowered with the resources and support needed to make better decisions about their healthcare and live a healthy life,' said A.R. Voss, Founder. 'Through our networked organizations, we will inspire hope and improve the quality of life of patients, their families and their caregivers through ongoing support, education and advocacy.' MHIF's advocacy efforts will focus on monitoring national and international legislative and regulatory changes, supporting ethical and legal reforms, backing alternate funding programs and organizing conferences to educate patient communities about healthcare policy changes. The Foundation will also build coalitions to help patients become empowered advocates for change. The Foundation will be governed by a Board of Directors with at least three members, along with auditors, the Mended Hearts International Advisory Committee and any other body designated by the MHIF Board. The Advisory Committee will include two representatives from each MHIN entity, one staff member serving as secretary and all MHIF Board members. For more information about the Mended Hearts International Foundation, contact info@ About Mended Hearts International Foundation The Mended Hearts International Foundation (MHIF) will be an independent, endowed, nonprofit foundation based in Geneva, Switzerland, established to coordinate global advocacy efforts for patients with cardiovascular disease and their families. The Foundation will work with national and international policymakers to develop patient-centered healthcare policies and regulatory frameworks. Additionally, MHIF will develop educational research projects, create educational resources and support patients and their families by creating an inclusive and compassionate community. It will also oversee the Mended Hearts International Network, which includes entities across multiple countries dedicated to providing peer-to-peer support, patient education and advocacy for cardiovascular patients worldwide. About Mended Hearts, Inc. The Mended Hearts, Inc. (MHI) is the world's largest peer-to-peer cardiovascular patient support network with more than 125,000 members residing in 73 countries. Founded in 1951 and incorporated in 1955, MHI's mission is 'to inspire hope and improve the quality of life of cardiovascular disease patients and their families through ongoing peer-to-peer support, education and advocacy.' MHI's three programs — Mended Little Hearts ®, Young Mended Hearts ®, and Mended Hearts ® — make MHI the only organization in the world that supports patients with all forms of cardiovascular diseases throughout a patient's entire lifespan. MHI volunteers personally inspire, educate and empower nearly 400,000 patients and family members in-person each year through a robust network of members who provide services and outreach in 643 hospitals, plus cardiology offices, clinics, cardiac rehab centers and local communities. MHI's support reaches another 7+ million individuals each year through social media channels, blogs, web pages and outreach. Beyond peer support, MHI serves as a trusted provider of patient education and resources, including HeartGuide ® patient and parent resource guides, interactive GoToGuides, trifold discussion guides, videos, webinars, Heartbeat ® magazine, and regional meetings and educational conferences. The MHI ACTION NETWORK™ brings together a community of patients, families, caregivers and researchers dedicated to advocating for those living with cardiovascular disease. For more information, visit
Business Wire
2 hours ago
- Business
- Business Wire
Brent H. Zettl Provides Update on Holdings of ZYUS Life Sciences Corporation
SASKATOON, Saskatchewan--(BUSINESS WIRE)--Mr. Brent H. Zettl (the ' acquiror '), who serves as the President and CEO and a director of ZYUS Life Sciences Corporation (' ZYUS ') provides updates to his holdings of Common shares (' Common Shares ') in the capital of ZYUS, Common Share purchase warrants of ZYUS (' Warrants ') and options to purchase Common Shares (' Options '). On June 27, 2025, the acquiror participated in a non-brokered private placement of units (' Units ') of ZYUS (the ' Private Placement ') at a price of $0.67 per Unit, with each Unit comprised of one Common Share and one half of one Warrant (each whole Warrant, a ' Private Placement Warrant '). Each Private Placement Warrant entitles the holder to acquire one Common Share at a price of $0.95 for a period of twenty-four months from the date of issuance, subject to certain acceleration provisions. The acquiror acquired, indirectly through 1189115 B.C. LTD. 298,507 Units (comprised of 298,507 Common Shares and 149,253 Warrants) under the Private Placement. Immediately prior to the Private Placement, the acquiror owned, directly and indirectly, and exercised control over 33,730,573 Common Shares and 493,108 Options, representing 43.9% of ZYUS's issued and outstanding Common Shares on an undiluted basis and 44.3% of ZYUS's issued and outstanding Common Shares on a partially diluted basis (assuming full exercise of all of the convertible securities held by the acquiror). Immediately following the Private Placement and as at the date hereof, the acquiror owns, directly and indirectly, and exercises control over 34,029,080 Common Shares, 149,253 Warrants and 493,108 Options, representing 43.9% of ZYUS's issued and outstanding Common Shares on an undiluted basis and 44.3% of ZYUS's issued and outstanding Common Shares on a partially diluted basis. Following the Private Placement, the acquiror's securityholding percentage has decreased by 1.4% on an undiluted basis from the percentage held immediately following the September 2024 Event (as defined below) and by 5.4% on an undiluted basis from the percentage disclosed in the last early warning report filed by the acquiror on June 13, 2023 (the ' 2023 EWR '), and has decreased by 1.6% on a partially diluted basis from the acquiror's securityholding percentage held immediately following the September 2024 Event and by 6.1% on a partially diluted basis from the acquiror's securityholding percentage as at June 13, 2023. The acquiror's securityholding percentage on a partially diluted basis as disclosed in the 2023 EWR (51.68%) was stated in error. The correct securityholding percentage on a partially diluted basis as at June 13, 2023 was 50.5%. Since the completion of the acquisition of ZYUS Life Sciences Inc. by ZYUS in June 2023, the acquiror's securityholding percentage on a partially diluted basis has decreased from 50.5% to his securityholding percentage immediately prior to the Private Placement as a result of certain transactions and events, including the two following transactions which resulted in each case in a decrease in the acquiror's securityholding percentage by 2% or more since the prior event: (i) on July 31, 2024, the acquiror, disposed of 470,000 Common Shares held by 102042227 Saskatchewan Ltd. (' 102 Sask '), an entity controlled by the acquiror to in satisfaction of payments due in the aggregate amount of $432,400 (the ' July 2024 Event '); and (ii) on September 4, 2024,14,088 Warrants with an exercise price of $3.55 per Common Share previously issued to 102 Sask on March 4, 2022 expired unexercised (the ' September 2024 Event '). Immediately prior to the July 2024 Event, the acquiror owned, directly and indirectly, and exercised control over 34,173,073 Common Shares, 292,933 Warrants and 493,108 Options, representing 48.2% of ZYUS's issued and outstanding Common Shares on an undiluted basis and 48.8% of ZYUS's issued and outstanding Common Shares on a partially diluted basis. Immediately following the July 2024 Event, the acquiror owned, directly and indirectly, and exercised control over 33,703,073 Common Shares, 292,933 Warrants and 493,108 Options, representing 47.6% of ZYUS's issued and outstanding Common Shares on an undiluted basis and 48.1% of ZYUS's issued and outstanding Common Shares on a partially diluted basis. Immediately following the July 2024 Event, the acquiror's securityholding percentage has decreased by 1.7% on an undiluted basis from the acquiror's securityholding percentage as at June 13, 2023 as disclosed in the 2023 EWR and has decreased by 2.3% on a partially diluted basis from the acquior's securityholding percentage as at June 13, 2023 (which was 50.5%). Immediately prior to the September 2024 Event, the acquiror owned, directly and indirectly, and exercised control over 33,703,073 Common Shares, 292,933 Warrants and 493,108 Options, representing 45.3% of ZYUS's issued and outstanding Common Shares on an undiluted basis and 45.9% of ZYUS's issued and outstanding Common Shares on a partially diluted basis. Immediately following the September 2024 Event, the acquiror owned, directly and indirectly, and exercised control over 33,703,073 Common Shares, 278,845 Warrants and 493,108 Options, representing 45.3% of ZYUS's issued and outstanding Common Shares on an undiluted basis and 45.9% of ZYUS's issued and outstanding Common Shares on partially diluted basis. Following the September 2024 Event, the acquiror's securityholding percentage has decreased by 2.3% on an undiluted basis from the percentage held immediately following the July 2024 Event and has decreased by 2.2% on a partially diluted basis from the percentage held immediately following the July 2024 Event. The Acquiror's transactions were made for investment purposes. The acquiror may, from time to time and at any time, acquire additional securities of ZYUS in the open market or otherwise, and may dispose of any or all of securities of ZYUS in the open market or otherwise at any time and from time to time, and to engage in similar transactions with respect to the securities of ZYUS, the whole depending on market conditions, the business and prospects of ZYUS and other relevant factors. An early warning report will be filed by the Acquiror under applicable securities laws and will be available on ZYUS's SEDAR+ profile at
Business Wire
6 hours ago
- Business
- Business Wire
SBC Medical added to membership of Russell 3000 ® Index
IRVINE, Calif.--(BUSINESS WIRE)-- SBC Medical Group Holdings Incorporated (Nasdaq: SBC) ('SBC Medical'), a global franchise and provider of services for aesthetic clinics, has been added as a member of the broad-market Russell 3000 ® Index, effective after the US market opens on June 30, as part of the 2025 Russell indexes reconstitution. Membership in the Russell 3000 ® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000 ® Index or small-cap Russell 2000 ® Index as well as the appropriate growth and value style indexes. Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. According to the data as of the end of June 2024, about $10.6 trillion in assets are benchmarked against the Russell US indexes, which belong to FTSE Russell, the global index provider. Fiona Bassett, CEO of FTSE Russell, An LSEG Business, comments: 'The Russell indexes have continuously adapted to the evolving dynamic US economy, and it's crucial to fully recalibrate the suite of Russell US Indexes, ensuring the indexes maintain an accurate representation of the market. The transition to a semi-annual reconstitution frequency from 2026 will ensure our indexes continue to represent the market and maintain the purpose of the index as a portfolio benchmark.' For more information on the Russell 3000 ® Index and the Russell indexes reconstitution, go to the 'Russell Reconstitution' section on the FTSE Russell website. About SBC Medical SBC Medical, headquartered in Irvine, California and Tokyo, Japan, owns and provides management services and products to cosmetic treatment centers. The Company is primarily focused on providing comprehensive management services to franchisee clinics, including but not limited to advertising and marketing needs across various platforms (such as social media networks), staff management (such as recruitment and training), booking reservations for franchisee clinic customers, assistance with franchisee employee housing rentals and facility rentals, construction and design of franchisee clinics, medical equipment and medical consumables procurement (resale), the provision of cosmetic products to franchisee clinics for resale to clinic customers, licensure of the use of patent-pending and non-patented medical technologies, trademark and brand use, IT software solutions (including but not limited to remote medical consultations), management of the franchisee clinic's customer rewards program (customer loyalty point program), and payment tools for the franchisee clinics. For more information, visit About FTSE Russell, an LSEG Business FTSE Russell is a global index leader that provides innovative benchmarking, analytics and data solutions for investors worldwide. FTSE Russell calculates thousands of indexes that measure and benchmark markets and asset classes in more than 70 countries, covering 98% of the investable market globally. FTSE Russell index expertise and products are used extensively by institutional and retail investors globally. Approximately $18.1 trillion is benchmarked to FTSE Russell indexes. Leading asset owners, asset managers, ETF providers and investment banks choose FTSE Russell indexes to benchmark their investment performance and create ETFs, structured products and index-based derivatives. A core set of universal principles guides FTSE Russell index design and management: a transparent rules-based methodology is informed by independent committees of leading market participants. FTSE Russell is focused on applying the highest industry standards in index design and governance and embraces the IOSCO Principles. FTSE Russell is also focused on index innovation and customer partnerships as it seeks to enhance the breadth, depth and reach of its offering. FTSE Russell is wholly owned by London Stock Exchange Group. For more information, visit FTSE Russell. Forward-Looking Statements This press release contains forward-looking statements. Forward-looking statements are not historical facts or statements of current conditions, but instead represent only the Company's beliefs regarding future events and performance, many of which, by their nature, are inherently uncertain and outside of the Company's control. These forward-looking statements reflect the Company's current views with respect to, among other things, the Company's product launch plans and strategies; growth in revenue and earnings; and business prospects. In some cases, forward-looking statements can be identified by the use of words such as 'may,' 'should,' 'expects,' 'anticipates,' 'contemplates,' 'estimates,' 'believes,' 'plans,' 'projected,' 'predicts,' 'potential,' 'targets' or 'hopes' or the negative of these or similar terms. The Company cautions readers not to place undue reliance upon any forward-looking statements, which are current only as of the date of this release and are subject to various risks, uncertainties, assumptions, or changes in circumstances that are difficult to predict or quantify. The forward-looking statements are based on management's current expectations and are not guarantees of future performance. The Company does not undertake or accept any obligation to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. Factors that may cause actual results to differ materially from current expectations may emerge from time to time, and it is not possible for the Company to predict all of them; such factors include, among other things, changes in global, regional, or local economic, business, competitive, market and regulatory conditions, and those listed under the heading 'Risk Factors' and elsewhere in the Company's filings with the U.S. Securities and Exchange Commission (the 'SEC'), which are accessible on the SEC's website at
Business Wire
6 hours ago
- Business
- Business Wire
SINOVAC Board of Directors Prevails Against Advantech/Prime's Lawsuit in Hong Kong
BEIJING--(BUSINESS WIRE)--The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ: SVA) (' SINOVAC ' or the ' Company '), a leading provider of biopharmaceutical products in China, today announced it has prevailed against the latest lawsuit filed by Advantech/Prime Success ('Advantech/Prime') in Hong Kong. This result follows Advantech/Prime's recently failed petition in New York last week, which was a repeated attempt by the purported PIPE Investors to block or delay a hearing for interim relief sought by the Company et al at the Antiguan High Court and to interfere with the payment of the US$55.00 per common share special cash dividend to valid shareholders of the Company as declared by the current SINOVAC Board. On June 24, Advantech/Prime delivered via email an ex parte Summons to SINOVAC, 1Globe Capital LLC ('1Globe') and OrbiMed Partners Master Fund Limited ('OrbiMed') for an 'interim-interim' injunction application (the 'Application'). Vivo Capital also sought to join the Application on June 26. After the emergent hearing at the High Court of Hong Kong on June 27, the court refused to grant any of the relief sought in the Summons. Among other things, the judge also criticized Advantech/Prime for: Failing to comply with the duty of full and frank disclosure in the Application; and The alleged urgency of the Application being self-induced by Advantech/Prime. The court also ordered that legal costs incurred in the Application by SINOVAC, 1Globe and OrbiMed be compensated by Advantech/Prime, with quantum to be assessed. Advantech/Prime's continued multi-jurisdictional lawfare is intended to interfere with rightful dividend payments to SINOVAC's valid shareholders and distract from its long history of self-serving schemes. These schemes include: Privatization attempt at a below-market price in 2016; Invalid PIPE transaction at a below-market price in 2018, which materially diluted SINOVAC shareholders and was made at a time when the Company did not need the capital; US$7.5 million debt investment into Sinovac Life Sciences Co., Ltd. ('SLS'), a wholly owned subsidiary of SINOVAC, in exchange for a 7.5% equity interest in SLS in 2020, at a time when the Company did not need the capital and which has resulted in over US$500 million of distributions made to Advantech/Prime to date while common shareholders have received nothing; and Baseless and wasteful legal action in 2025 to interfere with the dividend payment unless Advantech/Prime is able to double dip on dividends already received from SLS. The current SINOVAC Board remains committed to its mission of restoring fairness, delivering value, and protecting the rights of all valid shareholders. Your Vote is Important Your vote on or before July 8 will be about the future of SINOVAC, your receipt of your make-whole dividend payments in the near-term, and the long-term value of your investment. We urge you to keep SINOVAC's Board in place and vote on the WHITE proxy card ' AGAINST ' Proposal 1 to remove the current Board and ' AGAINST ' Proposal 2 to appoint the Reconstituted Imposter Former Board Slate. Your vote is critical to ensuring that SINOVAC remains on the path to stability, growth, and value creation for all shareholders. DISCARD any items you received asking you to vote for the Reconstituted Imposter Former Board Slate. If you have already voted for the Reconstituted Imposter Former Board Slate, you can subsequently revoke it by using the WHITE proxy card or WHITE voting instruction form to vote. Only your latest-dated vote will count! If you have questions about how your vote can be counted, please contact our proxy solicitor, Georgeson LLC, toll free at (844) 568-1506 in the U.S. and (646) 543-1968 outside the U.S. or via email at SinovacSpecialMeeting@ About SINOVAC Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases. SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected Hand-Foot-Mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, etc. The COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive®, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive®, is an innovative vaccine under "Category 1 Preventative Biological Products" and commercialized in China in 2016. In 2022, SINOVAC's Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the WHO. SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1®, which has supplied the Chinese government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu®, to the Chinese government stockpiling program. SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities. SINOVAC plans to conduct more extensive and in-depth trade and cooperation with additional countries, and business and industry organizations. Important Additional Information and Where to Find It In connection with SINOVAC's Special Meeting, SINOVAC has filed with the U.S. Securities and Exchange Commission ('SEC') and mailed to shareholders of record entitled to vote at the Special Meeting a definitive proxy statement and other documents, including a WHITE proxy card. SHAREHOLDERS ARE ENCOURAGED TO READ THE PROXY STATEMENT AND ALL OTHER RELEVANT DOCUMENTS WHEN FILED WITH THE SEC AND WHEN THEY BECOME AVAILABLE BECAUSE THOSE DOCUMENTS WILL CONTAIN IMPORTANT INFORMATION. Investors and other interested parties will be able to obtain the documents free of charge at the SEC's website, or from SINOVAC at its website: You may also obtain copies of SINOVAC's definitive proxy statement and other documents, free of charge, by contacting SINOVAC's Investor Relations Department at ir@ Safe Harbor Statement This announcement contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as 'may,' 'will,' 'expect,' 'anticipate,' 'aim,' 'estimate,' 'intend,' 'plan,' 'believe,' 'potential,' 'continue,' 'is/are likely to' or other similar expressions. Such statements are based upon current expectations and current market and operating conditions and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond the Company's or Board's control, which may cause actual results, performance or achievements to differ materially from those in the forward-looking statements. Further information regarding these and other risks, uncertainties or factors is included in the Company's filings with the U.S. Securities and Exchange Commission. The Company and Board do not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under law.
Business Wire
6 hours ago
- Business
- Business Wire
QUANTUM COMPUTING INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Quantum Computing Inc.
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ('KSF'), announces that KSF has commenced an investigation into Quantum Computing Inc. (NASDAQCM: QUBT). On January 16, 2025, Capybara Research reported a myriad of allegations against the Company including that it had overstated its ties to NASA and fabricated revenues through multiple related-party transactions, particularly with Quad M and millionways; that its products were fake, citing comments by former QCI personnel; and that it was pumping its stock price with false and misleading press releases, citing discussions with its former employees, associates and prime contractors, and NASA personnel. Thereafter, the Company and certain of its executives were sued in a securities class action lawsuit, charging them with failing to disclose material information in violation of federal securities laws, which remains ongoing. KSF's investigation is focusing on whether Quantum's officers and/or directors breached their fiduciary duties to its shareholders or otherwise violated state or federal laws. If you have information that would assist KSF in its investigation, or have been a long-term holder of Quantum shares and would like to discuss your legal rights, you may, without obligation or cost to you, call toll-free at 1-833-938-0905 or email KSF Managing Partner Lewis Kahn ( or visit to learn more. About Kahn Swick & Foti, LLC KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation's premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors - in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, New Jersey, and a representative office in Luxembourg. TOP 10 Plaintiff Law Firms - According to ISS Securities Class Action Services To learn more about KSF, you may visit
